TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
2024年9月5日 - 8:00PM
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology
company committed to more effectively treating cancer using RNA
therapeutics, today announced that it has been awarded a $2 million
Direct to Phase II Small Business Innovation Research (SBIR) grant
from the National Institutes of Health (NIH) to support clinical
evaluation of TTX-MC138, TransCode’s lead therapeutic candidate.
TransCode has recently activated three clinical trial sites to
conduct a Phase I/II clinical trial of TTX-MC138 for the treatment
of advanced solid tumors.
The clinical trial is designed to generate
critical data to support evaluation of the safety of TTX-MC138.
While efficacy of TTX-MC138 is not an endpoint in this trial, the
trial may nevertheless provide early evidence of TTX-MC138 clinical
activity in patients with metastatic disease. Funds under the grant
are expected to be received over two years.
“We are honored that the NIH recognizes and
continues to support our mission to advance therapies against
metastatic cancer,” said Zdravka Medarova, Ph.D., Chief Scientific
Officer of TransCode. “NIH funding is awarded only after rigorous
review. We believe that this award attests to the potential impact,
novelty, and robustness of the TTX-MC138 clinical development
program.”
TTX-MC138 is a first-in-class therapeutic
candidate with novel relevance to metastatic disease. Successful
clinical development of TTX-MC138 potentially represents a viable
treatment option for many patients with metastatic cancer.
About TransCode
Therapeutics
TransCode is a clinical-stage oncology company
focused on treating metastatic disease. The company is committed to
defeating cancer through the intelligent design and effective
delivery of RNA therapeutics based on its proprietary TTX
nanoparticle delivery platform. The company’s lead therapeutic
candidate, TTX-MC138, is focused on treating metastatic tumors
which overexpress microRNA-10b, a unique, well-documented biomarker
of metastasis. In addition, TransCode is developing a portfolio of
other first-in-class RNA therapeutic candidates designed to
overcome the challenges of RNA delivery and thus unlock therapeutic
access to a variety of novel genetic targets that could be relevant
to treating a variety of cancers.
Forward-Looking Statements
This release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, including, without limitation, statements
concerning the therapeutic potential of TransCode’s TTX-MC138 and
the conduct and results of the planned Phase I/II clinical trial.
Any forward-looking statements in this press release are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk associated
with drug discovery and development; the risk that the results of
our clinical trials will not be consistent with our pre-clinical
studies or expectations or with previous clinical trials; risks
associated with the timing and outcome of TransCode’s planned
regulatory submissions; risks associated with TransCode’s conduct
of clinical trials; risks associated with obtaining, maintaining
and protecting intellectual property; risks associated with
TransCode’s ability to enforce its patents against infringers and
defend its patent portfolio against challenges from third parties;
risks of competition from other companies developing products for
similar uses; risks associated with TransCode’s financial condition
and its need to obtain additional funding to support its business
activities, including TransCode’s ability to continue as a going
concern; risks associated with TransCode’s dependence on third
parties; and risks associated with geopolitical events and
pandemics, including the COVID-19 coronavirus. For a discussion of
these and other risks and uncertainties, and other important
factors, any of which could cause TransCode’s actual results to
differ from those contained in or implied by the forward-looking
statements, see the section entitled “Risk Factors” in TransCode’s
Annual Report on Form 10-K for the year ended December 31, 2023, as
well as discussions of potential risks, uncertainties and other
important factors in any subsequent TransCode filings with the
Securities and Exchange Commission. All information in this press
release is as of the date of the release; TransCode undertakes no
duty to update this information unless required by law.
For more information, please
contact:
TransCode Therapeutics, Inc.Tania Montgomery-Hammon, VP of
Business Developmenttania.montgomery@transcodetherapeutics.com
TransCode Therapeutics (NASDAQ:RNAZ)
過去 株価チャート
から 9 2024 まで 10 2024
TransCode Therapeutics (NASDAQ:RNAZ)
過去 株価チャート
から 10 2023 まで 10 2024